… single-agent activity in women with ovarian cancer in phase II trials. Response rates … ovarian
cancer. Phase III trials with many anti-angiogenic agents in the treatment of ovarian cancer …

… new ovarian cancer cases diagnosed and 13,770 ovarian cancer deaths in … antiangiogenic
agents that have led to the current status of treatment of advanced epithelial ovarian cancer. …

… a potential role for antiangiogenic agents in the management of epithelial ovarian cancer.
Following a brief overview of the current treatment of ovarian cancer and preclinical data …

… been conducted on a single antiangiogenic drug or advanced ovarian cancer. However, this
… of various antiangiogenic drugs for the treatment of patients with recurrent ovarian cancer. …

… types and specifically in epithelial ovarian cancer. In 2005, single-… high-grade serous
ovarian cancer after failing 11th line … patients with ovarian cancer will receive an anti-angiogenic …

… The fundamental targets of anti-angiogenic drugs are vascular endothelial growth factor …
and novel anti-angiogenic drugs that make the treatment of patients with ovarian cancer a …

… Data so far are promising regarding antiangiogenic therapies in the field of ovarian cancer;
however, much work has yet to be done. To date, the most promising data have arisen from …

… efficacy of antiangiogenic agents in advanced ovarian cancer. … -free survival when
antiangiogenic agents were used as a … use of antiangiogenic agents in advanced ovarian cancer. …

… The most investigated antiangiogenic agent to date is the humanized monoclonal … ovarian
cancer.To date, four phase III randomized clinical trials testing bevacizumab in ovarian cancer …

… Due to the high levels of intratumoral VEGF [7], target therapies binding VEGF represent
one of the most promising molecular drugs in ovarian cancer in last years. More recently, …